IDF is pleased to announce the recipients of the 2018 IDF Research Grants, which support well-defined research projects that have a specified benefit for improving the treatment, health, disease management or diagnosis of people with primary immunodeficiency diseases (PI).
- Lori Broderick, MD, PhD – University of California, San Diego, "Role of Topoisomerase 2 beta in human B cell development." The primary goal of her project is to understand how mutations in a single specific protein cause defects in the immune system.
- Megan A. Cooper, MD, PhD – St. Louis Children’s Hospital Foundation, "Novel genetic variants in pediatric patients with immune dysregulation.” The goal of this research will be understanding the molecular basis of pediatric immune dysregulation syndromes.
- Attila Kumanovics, MD - University of Utah, "CXCR2-Dependent Neutrophil Chemotaxis Defect in Hyper-IgE Syndrome." The goal of this research is to study STAT3-dependent neutrophil granulocyte migration to understand the immune defects in Hyper-IgE Syndrome.
- Carrie L. Lucas, PhD – Yale University, "Novel signaling aberrations in a novel primary immunodeficiency disorder." The goal of this research is to investigate the mechanistic link between the inherited mutations and defects in innate immunity that underlie disease.
Because of the dollars raised through IDF Walk for PI—more than $4 million since 2013—IDF was able to establish the IDF Research Grant Program.
We are eagerly looking forward to the results of all of these studies, and we hope to be able to share their successes with the PI community.
This article originally appeared in the IDF monthly e-newsletter, Primary Immune Tribune. Click here to subscribe.